On October 20, 2021 Patrys (ASX:PAB) reported that it has published its Quarterly Activities Report and 4C Quarterly Cash Flow Report, for the quarter ended 30 September 2021 (Press release, Patrys, OCT 20, 2021, View Source [SID1234591573]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Key highlights from this period include:

Studies confirm full-sized IgG deoxymab antibody, PAT-DX3 is able to cross the blood brain barrier in animal model of primary brain cancer
PAT-DX1 significantly improves survival in animal model of pancreatic cancer
Preclinical data highlights the potential for using PAT-DX3 as a targeting agent in antibody drug conjugates (ADCs)
Our Company had a cash and short-term investment balance of A$9.8M at 30 September 2021.